Castle Biosciences to Present New Data on DecisionDx-Melanoma at EADO and ACMS Meetings
Castle Biosciences announced it will present new data showing that its DecisionDx-Melanoma test can identify early-stage melanoma patients at greater risk of recurrence and poor outcomes. The findings will be shared at the European Congress of Dermato-Oncology and the American College of Mohs Surgery meetings.